Health and wellbeing company Satipharm has completed the second phase of their clinical trial into the effects of CBD on seizure frequency. The wholly-owned subsidiary of Canadian Cannabis company, HarvestOne, discovered an overall reduction in seizures among 16 paediatric patients.
Clinicians observed an average seizure reduction of 73.4%, with two patients becoming seizure-free in five weeks. A further seven patients experienced a reduction of more than 50%.
Phase 1 of the trial focused on the efficacy of Satipharm’s CBD Gelpell® capsule. The capsule contains a 50mg dose of full-spectrum Hemp extract CBD in a large number of soluble gelatine beads. These beads are then placed inside a hard gastro-resistant capsule, to ensure the release of the CBD in the small intestine.
The evidence collected from phase 1 of the trial proved that the Gelpell capsules increased the bioavailability of the CBD. This is because
... read more at: https://canex.co.uk/cbd-capsules-reduced-seizures-in-epileptic-children/